KORRO BIO INC

KRRONASDAQ

🏆 #2950 by market capEarnings Nov 10US Equity

$688.83▲ $3.65 (+0.53%)

Simulated price

1h—

24h▲ 0.5%

7d—

14d—

30d—

1y—

🏦Market Cap

$196M

Small Cap

📈Revenue Growth (YoY)

-62.1%

Declining

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

31.5x

Expensive

Otter Score

Weak

No chart data available for KRRO.

Trading Snapshot

Day Range: $678.46 – $691.60
52-Week Range: $5.20 – $55.89
Volume: $2.24B
Avg Volume: $2.20B
Shares Outstanding: 14.4M
Next Earnings: Sep 24, 2026

Fundamentals Snapshot

Annual Revenue: $6M
Last Q Revenue: $2M
P/E Ratio: —
P/S Ratio: 31.5x
EPS (TTM): $-10.00
Dividend Yield: —

Why Investors Own KRRO

✓High-growth profile — revenue up +20.8% YoY with expanding US Equity exposure.
✓Healthy economics — 32% gross margin and 7% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$6M▲ +17.5% YoY

Gross Margin (TTM)

32.2%▲ +2.6% YoY

Operating Income (TTM)

$2M▲ +17.5% YoY

Free Cash Flow (TTM)

$434,656▲ +17.5% YoY

About KORRO BIO INC

Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.

🦦